Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Symphogen opens US operations in Princeton, New Jersey


US subsidiary supports expanding opportunities for Symphogen’s novel antibody pipeline and discovery and expression platforms

COPENHAGEN, Denmark and PRINCETON, NJ (November 3, 2009): Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed Chief Business Officer, will head the Company’s US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.

“This is the optimal time to strengthen Symphogen’s global presence as our novel pipeline is advancing into the later-stages of clinical development,” said Kirsten Drejer, Ph.D., CEO of Symphogen.

Ms. Sax added, “Antibody therapeutics and technologies continue to drive significant value for the pharmaceutical industry. New Jersey has long been recognized as good centralized location for bioscience companies with global development programs and multiple worldwide partnerships, so it was an easy decision for Symphogen to base our US business here. With Symphogen’s growing pipeline and leading antibody discovery and expression technologies, we are excited about the company’s future prospects and hope to capitalize on these opportunities by having broad access to physicians, patients and partners.”

About Symphogen
Symphogen is developing superior antibody therapeutics to help people with serious diseases. With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease. Symphogen is a private biopharmaceutical company with more than 70 employees, and its headquarters are based in Copenhagen, Denmark. www.symphogen.com

Contacts:
Kirsten Drejer, CEO of Symphogen: +45 45 26 50 59 or +45 22 10 99 59 (cell); kd@symphogen.com

Media:
Karen Miller, Manager, US Business Operations: +1 609 951 2295 kmi@symphogen.com

Symphogen, Inc.
116 Village Blvd., Ste. 200
Princeton, NJ 08540


Publisher Contact Information:

Symphogen A/S
+1 609 951 2295
kmi@symphogen.com

Company profile of Symphogen A/S
Past press releases of Symphogen A/S.

Data


24,159
Tech investments
From our Online Data Service
15,619
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Apr 22€7.0MBusiness applications
Apr 20€1.3MeLearning
Apr 19€0.8MMaterials
Apr 19€16.5MMaterials
Apr 19€11.0MInternet commerce
Apr 19€35.5MBiopharmaceuticals
Apr 13€8.0MSecurity

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises €37.5 million in series a





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.